Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine

Simple item page
dc.contributor.authorPappas, P.en
dc.contributor.authorMavroudis, D.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorMarselos, M.en
dc.date.accessioned2015-11-24T19:30:08Z
dc.date.available2015-11-24T19:30:08Z
dc.identifier.issn0959-4973-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23026
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverseen
dc.subjecteffectsen
dc.subjectArea Under Curveen
dc.subjectDeoxycytidine/administration & dosage/adverse effects/*analogs &en
dc.subjectderivatives/pharmacokineticsen
dc.subjectDrug Interactionsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/drug therapyen
dc.subjectOrganoplatinum Compounds/*administration & dosage/adverse effectsen
dc.subjectPlatinum/blood/pharmacokineticsen
dc.subjectTreatment Outcomeen
dc.titleCoadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabineen
heal.abstractWe investigated the possible pharmacokinetic interactions of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ten patients with advanced stage solid tumors were treated with gemcitabine (1500 mg/m) as a 30-min intravenous infusion on days 1 and 8, followed by oxaliplatin (130 mg/m) as a 4-h intravenous infusion, on day 8 every 21 days. Pharmacokinetic data for 24 h after dosing were obtained for both day 1 (gemcitabine without oxaliplatin coadministration) and day 8 (gemcitabine with oxaliplatin) during the first cycle of treatment. Gemcitabine levels in plasma were quantified using a reverse-phase high-performance liquid chromatography assay with ultraviolet detection, and total and ultrafiltrated platinum levels by flameless atomic absorption spectrophotometry with deuterium correction. All pharmacokinetic parameters of gemcitabine seemed to be unchanged when coadministered with oxaliplatin (day 8) compared with pharmacokinetic data of gemcitabine given as a single agent (day 1). The mean (maximum) concentration of gemcitabine on days 1 and 8 was 13.57 (+/-7.42) and 10.23 (+/-5.21) mg/l, respectively (P=0.28), and the mean half-life was 0.32 and 0.44 h, respectively (P=0.40). Similarly, the P-values for AUC0-24 and the observed clearance were 0.61 and 0.30, respectively. Plasma total and free platinum levels were in agreement with other published data. Gemcitabine disposition appeared to be unaffected by oxaliplatin coadministration because no significant changes in pharmacokinetics between day 1 (gemcitabine without oxaliplatin coadministration) and day 8 (gemcitabine with oxaliplatin) were observed.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1097/01.cad.0000236303.97467.49-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17075318-
heal.journalNameAnticancer Drugsen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ